Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 18, 2012, Pages 2218-2226

  Hassett, Michael J ^a   Silver, Samuel M ^b   Hughes, Melissa E ^a   Blayney, Douglas W ^f   Edge, Stephen B ^h   Herman, James G ^c   Hudis, Clifford A ⁱ   Marcom, P Kelly ^j   Pettinga, Jane E ^d   Share, David ^e   Theriault, Richard ^k   Wong, Yu Ning ^l   Vandergrift, Jonathan L ^m   Niland, Joyce C ^g   Weeks, Jane C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c Department of Medical Oncology and Hematology   (United States)

^d SPECTRUM HEALTH   (United States)

^e BlueCross BlueShield of Michigan   (United States)

^f STANFORD CANCER INSTITUTE   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j DUKE CANCER INSTITUTE   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l FOX CHASE CANCER CENTER   (United States)

^m National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; EDUCATIONAL STATUS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EUROPEAN AMERICAN; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRIORITY JOURNAL; RACE DIFFERENCE;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION PROFILING; HEALTHCARE DISPARITIES; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; TIME FACTORS; YOUNG ADULT;

EID: 84864021927     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.5740     Document Type: Article

References (42)

1. National Cancer Institute: Dictionary of Cancer Terms. http://www.cancer.gov/dictionary/?CdrID=561717
2. Collins FS, Morgan M, Patrinos A: The Human Genome Project: Lessons from large-scale biology. Science 300:286-290, 2003 (Pubitemid 36433711)
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
4. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
5. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
6. Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
7. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007 (Pubitemid 350232263)
8. Carlson RW, Allred DC, Anderson BO, et al: Invasive breast cancer. J Natl Compr Canc Netw 9:136-222, 2011
9. Ademuyiwa FO, Miller A, O'Connor T, et al: The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 126:797-802, 2011
10. Lo SS, Mumby PB, Norton J, et al: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676, 2010
11. Kelly CM, Krishnamurthy S, Bianchini G, et al: Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116:5161-5167, 2010
12. Weeks JC: Outcomes assessment in the NCCN. Oncology (Williston Park) 11:137-140, 1997
13. Niland JC. NCCN Internet-based data system for the conduct of outcomes research. Oncology (Williston Park) 12:142-146, 1998
14. Christian CK, Niland J, Edge SB, et al: A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: A study of the National Comprehensive Cancer Network. Ann Surg 243:241-249, 2006 (Pubitemid 43185444)
15. Edge SB, Niland JC, Bookman MA, et al: Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 95:1514-1521, 2003 (Pubitemid 37322094)
16. Weeks J: Outcomes assessment in the NCCN: 1998 update - National Comprehensive Cancer Network. Oncology (Williston Park) 13:69-71, 1999
17. Silver SM, Mehringer AM, Hayes A, et al: Michigan Breast Oncology Quality Initiative (MiBOQI): A state-wide multidisciplinary breast cancer quality initiative - Concordance with quality measures. American Society of Clinical Oncology 2009 Breast Cancer Symposium, San Francisco, CA, October 8-10, 2009 (abstr 164)
18. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 40:373-383, 1987 (Pubitemid 17055592)
19. Katz JN, Chang LC, Sangha O, et al: Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34:73-84, 1996 (Pubitemid 126433198)
20. Sparano JA: TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350, 2006
21. Du X, Goodwin JS: Patterns of use of chemotherapy for breast cancer in older women: Findings from Medicare claims data. J Clin Oncol 19:1455-1461, 2001 (Pubitemid 32202553)
22. Harlan LC, Clegg LX, Abrams J, et al: Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 24:872-877, 2006 (Pubitemid 46638838)
23. Hassett MJ, Hughes ME, Niland JC, et al: Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. J Clin Oncol 26:5553-5560, 2008
24. Hébert-Croteau N, Brisson J, Latreille J, et al: Time trends in systemic adjuvant treatment for node-negative breast cancer. J Clin Oncol 17:1458-1464, 1999 (Pubitemid 29220852)
25. Mariotto A, Feuer EJ, Harlan LC, et al: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 94:1626-1634, 2002 (Pubitemid 35378728)
26. Cardoso F, Piccart-Gebhart M, Van't Veer L, et al: The MINDACT trial: The first prospective clinical validation of a genomic tool. Mol Oncol 1:246-251, 2007 (Pubitemid 350181650)
27. Southwest Oncology Group (SWOG): SWOG RxPONDER Trial (S1007): Patient Information. http://www.swog.org/Visitors/S1007/patients.asp
28. Tsoi DT, Inoue M, Kelly CM, et al: Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 15:457-465, 2010
29. Oestreicher N, Ramsey SD, Linden HM, et al: Gene expression profiling and breast cancer care: What are the potential benefits and policy implications? Genet Med 7:380-389, 2005 (Pubitemid 41139621)
30. Lyman GH, Cosler LE, Kuderer NM, et al: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018, 2007 (Pubitemid 46435378)
31. Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11:313-324, 2005 (Pubitemid 40646936)
32. Cosler LE, Lyman GH: Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest 27:953-959, 2009
33. Kulin NA, Marshall DA, Fenwick E, et al: Cost-effectiveness of gene expression profiling in early breast cancer. 32nd Annual Meeting of the Society for Medical Decision Making, Toronto, Ontario, Canada, October 24-27, 2010
34. Mikhail N, Cope D: The JNC-7 guidelines and the optimal target for systolic blood pressure. Hypertension 43:e31, 2004
35. Garber K: Ready or not: Personal tumor profiling tests take off. J Natl Cancer Inst 103:84-86, 2011
36. Lavery I, Hammel J, Cowens, J, et al: Relationship between tumor gene expression and recurrence in an observational cohort of patients with stage II/III colon cancer treated with surgery only: Quantitative RT-PCR assay of 375 genes in fixed paraffin-embedded (FPE) tissue. American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008 (abstr 302)
37. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002
38. Pass HI, Liu Z, Wali A, et al: Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10:849-859, 2004 (Pubitemid 38198883)
39. Wang Y, Klijn JG, Zhang Y, et al: Geneexpression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005
40. de la Chapelle A, Hampel H: Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28:3380-3387, 2010
41. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
42. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010